期刊文献+

骨向分化骨髓间充质干细胞的免疫学特性研究

Immunologic properties of osteogenic differentiated bone mesenchymal stem cells
原文传递
导出
摘要 目的探讨骨向分化骨髓问充质干细胞(bonemesenchymalstemcells,BMSCs)的免疫学特性。方法正常成人骨髓分离的BMSCs在骨向诱导培养基中培养2周后,将未分化的BMSCs和骨向分化的BMSCs与同种异体T淋巴细胞、植物血凝素(PHA)共培养,MrITr法检测T淋巴细胞的增殖情况;ELISA法测定骨向分化2周的BMSCs上清以及共同反应5d的混合淋巴细胞反应(mixedlymphocytesreaction,MLR)上清转化生长因子(transforminggrowthfactor-β1,TGF—β1)的浓度,并通过加入抗TGF—β抗体检测MLR情况。结果无论是未分化的BMSCs还是骨向分化的BMSCs都不会引起同种异体T淋巴细胞的增殖,并且都能抑制PHA诱导的T淋巴细胞增殖。MLR中的TGF-β1浓度显著升高。抗TGF—β抗体能够抵消骨向分化的BMSCs免疫抑制作用。结论骨向分化的BMSCs具有低免疫原性和免疫抑制特性。 Objective To investigate the immunologic properties of osteogenic differentiated bone mesenchymal stem ceils (BMSCs). Methods BMSCs were isolated from normal volunteers and in- duced in osteogenic medium for two weeks. Then, non-differentiated/osteogenic differentiated BMSCs were co-cultured with allogenic T cells and phytohemagglutinin (PHA). The proliferation of T cells was examined by MTY method. The concentrations of TGF-β1 in osteogenic differentiated BMSCs supernatants at week 2 and mixed lymphocytes reaction (MLR) supernatants at day 5 were determined by ELISA. Al- so, anti-TGF-β antibody was added into the MLR to detect the response of the mixed T cells. Results Non-differentiated and osteogenic differentiated BMSCs did not induce proliferation of the allogeneic T cells but both suppressed the proliferation of the T cells mediated by PHA. The TGF-β1 concentrations had significant elevation in the MLR. Anti-TGF-β antibody could counteract the immunosuppressive func- tion of the osteogenic differentiated BMSCs. Conclusion Osteogenic differentiated BMSCs possess low immunogenicity and immunosuppressive property.
出处 《中华创伤杂志》 CAS CSCD 北大核心 2012年第9期838-841,共4页 Chinese Journal of Trauma
基金 国家自然科学基金资助项目(81070799) 山东省优秀中青年科学家科研奖励基金资助项目(BS2010SW033)
关键词 骨髓 间质干细胞 细胞分化 免疫抑制 Bone marrow Mesenchymal stem cells Cell differentiation Immunosuppression
  • 相关文献

参考文献16

  • 1Pittenger MF, Mackay AM, Beck SC, et al. Muhilineage potential of adult human mesenchymal stem cells. Science, 1999, 284 (5411) :143 -147.
  • 2Di Nicola M, Carlo - Stella C, Magni M, et al. Human bone mar- row stromal cells suppress T- lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 2002, 99 (10) : 3838 - 3843.
  • 3Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenehy- real stem cells inhibit the response of naive and memory antigen - specific T cells to their cognate peptide. Blood, 2003, 101 ( 9 ) : 3722 - 3729.
  • 4Aggarwal S, Pittinger MF. Human mesenehymal stem cells modu- late allogeneie immune cell responses. Blood, 2005, 105 ( 4 ) : 1815 - 1822.
  • 5Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 2002, 30( 1 ) :42 -48.
  • 6Kidd S, Caldwell L, Dietrich M, et al. Mesenchymal stromal cells alone or expressing interferon - beta suppress pancreatic tumors in vivo, an effect countered by anti - inflammatory treatment. Cyto- therapy, 2010, 12(5) :615 -625.
  • 7Chen Y, Shao JZ, Xiang LX, et al. Mesenchymal stem ceils: a promising candidate in regenerative medicine. Int J Biochem Cell Biol, 2008, 40(5) : 815 -820.
  • 8Trounson A, Thakar RG, Lomax G, et al. Clinical trials for stem cell therapies. BMC Med, 2011, 9:52.
  • 9Buja LM, Vela D. Immunologic and inflammatory reactions to exog- enous stem ceils implications for experimental studies and clinical trials for myocardial repair. J Am Coil Cardiol, 2010, 56(21 ) : 1693 - 1700.
  • 10Kebriaei P, Robinson S. Treatment of graft - versus - host - dis- ease with mesenchymal stromal cells. Cytotherapy, 2011, 13 ( 3 ) : 262 - 268.

二级参考文献10

  • 1Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells[].Science.1999
  • 2Deans R J,Moseley A B.Mesenchymal stem cells: biology and potential clinical uses[].Experimental Hematology.2000
  • 3Janssens S,Dubois C,Bogaert J,et al.Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial[].The Lancet.2006
  • 4Stamm C,Westphal B,Kleine HD,et al.Autologous bone-marrow stem-cell transplantation for myocardial regeneration[].The Lancet.2003
  • 5Horwitz EM,Prockop DJ,Fitzpatrick LA,et al.Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta[].Nature Medicine.1999
  • 6Quarto R,Mastrogiacomo M,Cancedda R,et al.Repair of large bone defects with the use of autologous bone marrow stromal cells[].New England Journal of Medicine The.2001
  • 7Wakitani S,Imoto K,Yamamoto T,et al.Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees[].Osteoarthritis and Cartilage.2002
  • 8Badiavas EV,Falanga V.Treatment of chronic wounds with bone marrow-derived cells[].Archives of Dermatology.2003
  • 9Tateishi-Yuyama E,Matsubara H,Murohara T,et al.Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized control trial[].LancetThe.2002
  • 10Di Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[].Blood.2002

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部